The amyloid β-protein precursor and Alzheimer's disease. Therapeutic approaches

D. Del Toro, M. Coma, I. Uribesalgo, F. X. Guix, F. J. Muñoz

Producció científica: Article en revista indexadaArticle de revisió (sistemàtica)Avaluat per experts

12 Cites (Scopus)


Alzheimer's disease (AD) is triggered by the pathophysiological cleavage of a single transmembrane glycoprotein denominated amyloid β-protein precursor (AβPP) rendering amyloid β-peptide (Aβ) that aggregates in β-sheets forming the neuritic plaques. Since AβPP is playing a key role in AD development, this review will be focused in the structure, proteolytic processing, related secretases, mutations, localization and physiological role of AβPP protein. AβPP is present in several tissues and can be spliced at different exons rendering up to ten AβPP isoforms. The most abundant isoforms are AβPP770, AβPP751 and AβPP695, being the last one the predominant isoform in neurons. Mutations in the AβPP sequence or in the secretases that cleavage AβPP determinate an early onset of AD. AβPP and the secretase activities involve in the non amyloidogenic and the amyloidogenic pathways are putative therapeutic targets in AD, but their relationships with other physiological functions can produce controversial results.

Idioma originalAnglès
Pàgines (de-a)271-283
Nombre de pàgines13
RevistaCurrent Medicinal Chemistry - Central Nervous System Agents
Estat de la publicacióPublicada - de des. 2005
Publicat externament


Navegar pels temes de recerca de 'The amyloid β-protein precursor and Alzheimer's disease. Therapeutic approaches'. Junts formen un fingerprint únic.

Com citar-ho